CTKB
Cytek Biosciences, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Buy
+51/100
Last price
5.35
▼ 0.74 (12.15%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
6.18
Prev close
6.09
Day high
6.21
Day low
5.36
Volume
2.05M
Market cap
$699.31M
P/E (TTM)
—
52W range
3.31 – 6.21
Day trading desk
Gap from prior close
+1.48%
Prior close 6.09
VWAP
5.59
-4.26% from price
Relative volume
1.71×
Unusually busy
Session range
20.94%
5.30 – 6.41
Position in range
5%
Near session low
ATR (14D)
0.31
5.83% of price
Prior day high
6.11
PDH
Prior day low
5.82
PDL
Bid / ask spread
—
Quote not published
Session volume
1.73M
Avg 1.01M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-6.60%
-8.5%
1M
+14.47%
+13.3%
3M
+22.55%
+18.0%
6M
+16.96%
-1.2%
YTD
+6.53%
-7.7%
1Y
+35.52%
+19.1%
3Y
-2.54%
-84.8%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on CTKB open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
11.01M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 18, 26 | YAN MING Chief Technology Officer |
— | 33.27K | — | Direct |
| Aug 18, 26 | MCCOMBE WILLIAM D. Chief Financial Officer |
— | 35.42K | — | Direct |
| Aug 18, 26 | MUIR GLENN P Director |
— | 3.09K | — | Direct |
| Aug 18, 26 | CHIN RICHARD M.D. PH.D. Director |
— | 6.11K | — | Direct |
| Aug 18, 26 | HOLDER MICHAEL Director |
— | 2.18K | — | Direct |
| Aug 18, 26 | JIANG WENBIN Chief Executive Officer |
— | 120.09K | — | Direct |
| Jun 12, 26 | YAN MING Chief Technology Officer |
STOCK | 135.89K | $0 | Direct |
| Jun 10, 26 | IMPER VERA Director |
— | 43.97K | — | Direct |
| Jun 10, 26 | NEFF DEBORAH J Director |
— | 43.97K | — | Direct |
| Jun 10, 26 | HOLDER MICHAEL Director |
— | 43.97K | — | Direct |
| Jun 10, 26 | BALL JACK Director |
— | 43.97K | — | Direct |
| May 18, 26 | YAN MING Chief Technology Officer |
— | 22.18K | — | Direct |
| May 18, 26 | MCCOMBE WILLIAM D. Chief Financial Officer |
— | 25.72K | — | Direct |
| May 18, 26 | BUSQUE PHILIPPE PH.D. Officer |
— | 10.46K | — | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BALL JACK |
Director | 86.68K | Conversion of Exercise of derivative security |
BARNETT VALERIE |
Officer | 150.01K | Conversion of Exercise of derivative security |
BUSQUE PHILIPPE PH.D. |
Officer | 43.47K | Conversion of Exercise of derivative security |
HOLDER MICHAEL |
Director | 62.88K | Conversion of Exercise of derivative security |
IMPER VERA |
Director | 59.68K | Conversion of Exercise of derivative security |
JIANG WENBIN |
Chief Executive Officer | 5.56M | Conversion of Exercise of derivative security |
MCCOMBE WILLIAM D. |
Chief Financial Officer | 134.69K | Conversion of Exercise of derivative security |
NEFF DEBORAH J |
Director | 59.68K | Conversion of Exercise of derivative security |
POIRSON ALLEN |
Officer | 59.98K | Conversion of Exercise of derivative security |
YAN MING |
Chief Technology Officer | 4.82M | Conversion of Exercise of derivative security |
Fundamentals
Market cap$699.31M
Enterprise value$463.77M
Revenue (TTM)$206.71M
Gross profit$107.23M
EBITDA$-39.76M
Net income$-80.58M
EPS (TTM)$-0.62
Free cash flow$9.30M
Total cash$262.00M
Total debt$26.46M
Book value / share$2.48
Shares outstanding129.98M
Float102.94M
Short % of float5.10%
Dividend yield0.00%
Beta (5Y)1.16
Valuation & profitability ratios
Trailing P/E—
Forward P/E76.86
PEG ratio—
Price / sales—
Price / book2.17
EV / revenue2.24
EV / EBITDA-11.66
Gross margin51.88%
Operating margin-29.50%
Profit margin-38.98%
Return on equity-23.04%
Return on assets-6.31%
Debt / equity8.22
Current ratio4.48
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $201.49M | $200.45M | $193.01M | $164.04M | +0.5% |
| Operating revenue | $201.49M | $200.45M | $193.01M | $164.04M | +0.5% |
| Cost of revenue | $97.03M | $89.35M | $83.59M | $63.06M | +8.6% |
| Gross profit | $104.46M | $111.11M | $109.43M | $100.97M | -6.0% |
| Research & development | $36.47M | $39.40M | $44.15M | $34.86M | -7.4% |
| Selling, general & admin | $108.38M | $92.23M | $93.12M | $67.92M | +17.5% |
| Total operating expense | $144.84M | $131.63M | $137.27M | $102.78M | +10.0% |
| Operating income | -$40.38M | -$20.52M | -$27.84M | -$1.80M | -96.8% |
| Net interest income | $1.74M | $10.36M | $4.34M | $2.05M | -83.2% |
| Pre-tax income | -$29.84M | -$5.70M | -$15.71M | $1.26M | -423.5% |
| Tax provision | $36.70M | $320.00K | -$3.56M | -$1.22M | +11,368.1% |
| Net income | -$66.54M | -$6.02M | -$12.15M | $2.58M | -1,005.3% |
| Net income to common | -$66.54M | -$6.02M | -$12.15M | $2.58M | -1,005.3% |
| Basic EPS | -0.52 | -0.05 | -0.09 | 0.02 | -940.0% |
| Diluted EPS | -0.52 | -0.05 | -0.09 | 0.02 | -940.0% |
| EBIT | -$29.37M | -$20.52M | -$13.64M | $3.83M | -43.1% |
| EBITDA | -$17.39M | -$10.03M | -$4.41M | $9.49M | -73.3% |
| Basic shares | 127.75M | 130.61M | 130.71M | 134.51M | -2.2% |
| Diluted shares | 127.75M | 130.61M | 130.71M | 138.56M | -2.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $90.85M | $98.72M | $167.30M | $296.60M | -8.0% |
| Cash & short-term investments | $261.53M | $277.86M | $262.41M | $341.15M | -5.9% |
| Accounts receivable | $62.51M | $60.59M | $55.93M | $48.86M | +3.2% |
| Inventory | $48.43M | $43.89M | $60.88M | $48.15M | +10.3% |
| Total current assets | $392.00M | $396.45M | $392.06M | $454.02M | -1.1% |
| Property, plant & equipment | $29.32M | $28.13M | $29.26M | $27.57M | +4.2% |
| Goodwill & intangibles | $33.52M | $36.79M | $39.27M | $14.47M | -8.9% |
| Total assets | $461.54M | $499.50M | $494.46M | $519.48M | -7.6% |
| Total current liabilities | $77.80M | $67.66M | $56.23M | $49.04M | +15.0% |
| Current debt | $6.30M | $4.66M | $565.00K | $580.00K | +35.2% |
| Long-term debt | $525.00K | $1.05M | $1.65M | $2.27M | -50.0% |
| Total debt | $23.74M | $17.02M | $14.14M | $18.09M | +39.5% |
| Total liabilities | $119.80M | $103.76M | $101.39M | $93.93M | +15.5% |
| Retained earnings | -$101.74M | -$35.20M | -$29.18M | -$17.03M | -189.0% |
| Shareholder equity | $341.74M | $395.74M | $393.06M | $425.30M | -13.6% |
| Working capital | $314.19M | $328.78M | $335.83M | $404.98M | -4.4% |
| Net tangible assets | $308.22M | $358.95M | $353.80M | $410.82M | -14.1% |
| Shares issued | 128.55M | 129.21M | 130.71M | 135.37M | -0.5% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$66.54M | -$6.02M | -$12.15M | $2.48M | -1,005.3% |
| Depreciation & amortisation | $11.97M | $10.49M | $9.23M | $5.66M | +14.2% |
| Stock-based compensation | $24.59M | $26.85M | $22.05M | $16.59M | -8.4% |
| Change in working capital | -$4.79M | $7.71M | -$10.51M | -$39.93M | -162.2% |
| Operating cash flow | -$4.69M | $25.38M | $5.28M | -$12.23M | -118.5% |
| Capital expenditure | -$4.19M | -$3.73M | -$4.83M | -$9.87M | -12.4% |
| Investing cash flow | $10.12M | -$82.97M | -$93.89M | -$55.91M | +112.2% |
| Share buybacks | -$15.07M | -$21.61M | -$44.15M | $0 | +30.2% |
| Financing cash flow | -$13.43M | -$15.82M | -$41.81M | $5.51M | +15.1% |
| Free cash flow | -$8.88M | $21.65M | $454.00K | -$22.10M | -141.0% |
| End cash position | $90.85M | $98.75M | $167.63M | $299.50M | -8.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $48.14M | $44.13M | $62.14M | $52.29M | $45.60M | +9.1% |
| Operating revenue | $48.14M | $44.13M | $62.14M | $52.29M | $45.60M | +9.1% |
| Cost of revenue | $19.80M | $22.88M | $29.26M | $24.74M | $21.73M | -13.5% |
| Gross profit | $28.34M | $21.25M | $32.88M | $27.55M | $23.87M | +33.3% |
| Research & development | $9.74M | $9.60M | $8.96M | $8.96M | $8.83M | +1.4% |
| Selling, general & admin | $30.00M | $30.11M | $29.52M | $27.79M | $25.66M | -0.4% |
| Total operating expense | $39.74M | $39.72M | $38.48M | $36.74M | $34.49M | +0.1% |
| Operating income | -$11.40M | -$18.46M | -$5.59M | -$9.19M | -$10.62M | +38.3% |
| Net interest income | $538.00K | $525.00K | $1.30M | $79.00K | $141.00K | +2.5% |
| Pre-tax income | -$11.64M | -$17.37M | -$4.03M | -$7.77M | -$6.78M | +33.0% |
| Tax provision | $515.00K | $1.49M | $40.05M | -$2.29M | -$1.19M | -65.5% |
| Net income | -$12.16M | -$18.87M | -$44.08M | -$5.48M | -$5.58M | +35.6% |
| Net income to common | -$12.16M | -$18.87M | -$44.08M | -$5.48M | -$5.58M | +35.6% |
| Basic EPS | -0.09 | -0.15 | -0.34 | -0.04 | -0.04 | +40.0% |
| Diluted EPS | -0.09 | -0.15 | -0.34 | -0.04 | -0.04 | +40.0% |
| EBIT | -$11.36M | -$17.11M | -$4.76M | -$7.28M | -$6.36M | +33.6% |
| EBITDA | -$8.38M | -$14.30M | -$1.71M | -$4.21M | -$3.37M | +41.4% |
| Basic shares | 129.46M | 128.70M | 128.17M | 127.55M | 126.93M | +0.6% |
| Diluted shares | 129.46M | 128.70M | 128.17M | 127.55M | 126.93M | +0.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $73.85M | $65.67M | $90.85M | $93.28M | $75.47M | +12.5% |
| Cash & short-term investments | $262.00M | $262.23M | $261.53M | $261.73M | $262.02M | -0.1% |
| Accounts receivable | $49.70M | $51.90M | $62.51M | $56.63M | $56.23M | -4.2% |
| Inventory | $52.25M | $49.79M | $48.43M | $51.65M | $49.49M | +4.9% |
| Total current assets | $377.93M | $379.30M | $392.00M | $388.49M | $382.82M | -0.4% |
| Property, plant & equipment | $31.76M | $31.11M | $29.32M | $29.20M | $34.74M | +2.1% |
| Goodwill & intangibles | $31.55M | $32.39M | $33.52M | $34.37M | $35.31M | -2.6% |
| Total assets | $446.93M | $449.11M | $461.54M | $494.92M | $493.32M | -0.5% |
| Total current liabilities | $84.33M | $80.94M | $77.80M | $75.21M | $73.27M | +4.2% |
| Current debt | $9.43M | $10.71M | $6.30M | $7.58M | $5.44M | -12.0% |
| Long-term debt | $246.00K | $386.00K | $525.00K | $655.00K | $791.00K | -36.3% |
| Total debt | $26.46M | $27.48M | $23.74M | $24.83M | $23.68M | -3.7% |
| Total liabilities | $124.98M | $121.47M | $119.80M | $116.35M | $115.76M | +2.9% |
| Retained earnings | -$132.76M | -$120.60M | -$101.74M | -$57.66M | -$52.18M | -10.1% |
| Shareholder equity | $321.95M | $327.64M | $341.74M | $378.57M | $377.56M | -1.7% |
| Working capital | $293.60M | $298.37M | $314.19M | $313.28M | $309.56M | -1.6% |
| Net tangible assets | $290.40M | $295.25M | $308.22M | $344.20M | $342.25M | -1.6% |
| Shares issued | 129.98M | 129.14M | 128.55M | 127.86M | 127.19M | +0.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$12.16M | -$18.87M | -$44.08M | -$5.48M | -$5.58M | +35.6% |
| Depreciation & amortisation | $2.98M | $2.81M | $3.04M | $3.06M | $2.99M | +6.1% |
| Stock-based compensation | $5.34M | $4.86M | $5.53M | $5.64M | $6.79M | +9.8% |
| Change in working capital | $4.19M | $9.00M | -$3.48M | -$3.56M | -$785.00K | -53.4% |
| Operating cash flow | $1.37M | -$2.74M | -$771.00K | -$3.90M | $108.00K | +150.0% |
| Capital expenditure | -$2.24M | -$2.20M | -$1.03M | -$655.00K | -$1.65M | -2.0% |
| Investing cash flow | $7.02M | -$27.08M | -$1.84M | $18.92M | -$16.41M | +125.9% |
| Share buybacks | $0 | $0 | $34.00K | $29.00K | -$4.51M | — |
| Financing cash flow | -$814.00K | $3.98M | -$1.23M | $1.94M | -$2.60M | -120.4% |
| Free cash flow | -$877.00K | -$4.94M | -$1.80M | -$4.55M | -$1.54M | +82.2% |
| End cash position | $73.85M | $65.67M | $90.85M | $93.28M | $75.47M | +12.5% |
Options analytics
Put / call volume
0.60
Call-heavy session
Put / call open interest
0.00
Positioning, not flow
Max pain
2.50
-53.5% from spot
ATM implied vol
0.0%
Nearest strike to spot
Skew (10% OTM)
+12.5%
Puts bid over calls
Call volume
5
Contracts, this expiry
Put volume
3
Contracts, this expiry
Heaviest call OI
2.50
7 contracts
Heaviest put OI
2.50
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.02 | -0.03 | -55.0% |
| Mar 2026 | -0.08 | -0.10 | -20.0% |
| Dec 2025 | 0.02 | -0.29 | -2,014.7% |
| Sep 2025 | 0.01 | -0.00 | -103.0% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.07 | 2 | $52.95M | +1.3% |
| Next quarter | 0.03 | 1 | $63.65M | +2.4% |
| Current year | -0.12 | 1 | $209.43M | +3.9% |
| Next year | 0.07 | 1 | $223.24M | +6.6% |
Analyst targets & ownership
Mean target$5.56
High target$7.50
Low target$4.75
Implied upside3.97%
Analyst count4
ConsensusNONE
Strong buy / Buy1 / 1
Hold2
Sell / Strong sell0 / 0
Held by insiders8.47%
Held by institutions62.95%
Institutions holding208
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
5.77
-7.23% from price
SMA 20
5.38
-0.08% from price
SMA 50
4.89
+10.01% from price
SMA 100
4.55
+17.50% from price
SMA 200
4.62
+16.39% from price
EMA 12
5.64
-5.07% from price
EMA 26
5.35
+0.03% from price
EMA 50
5.05
+5.86% from price
RSI (14)
51.2
Neutral
MACD (12,26,9)
0.29
Hist 0.00
ATR (14)
0.31
5.80% of price
Realised vol 30D
55.0%
Annualised
Bollinger upper
6.33
20, 2σ
Bollinger lower
4.44
20, 2σ
50 / 200 cross
Golden
4.89 vs 4.62
Trend bias
Above 200
+16.39%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.87
Less volatile than market
Correlation to SPY
0.20
Largely independent
Realised vol 30D
55.0%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-42.9%
Peak to trough
Max drawdown 5Y
-90.3%
Peak to trough
ATR 14
0.31
5.80% of price
Beta (reported)
1.16
5Y monthly, from filing
Short interest
Shares short
5.24M
Prior 4.99M
Change vs prior
+5.1%
Shorts adding
% of float
5.10%
Normal
% of shares out
4.03%
Against total outstanding
Days to cover
6.3
Crowded exit
Float
102.94M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 13, 26 | Stephens & Co. | MAINTAINED | Overweight | Overweight |
| May 12, 26 | Morgan Stanley | MAINTAINED | Equal-Weight | Equal-Weight |
| Jan 8, 26 | TD Cowen | MAINTAINED | Buy | Buy |
| Nov 11, 25 | Piper Sandler | MAINTAINED | Overweight | Overweight |
| May 28, 25 | Morgan Stanley | MAINTAINED | Equal-Weight | Equal-Weight |
| May 12, 25 | Goldman Sachs | MAINTAINED | Sell | Sell |
| Mar 19, 25 | Stephens & Co. | MAINTAINED | Overweight | Overweight |
| Mar 4, 25 | Piper Sandler | MAINTAINED | Overweight | Overweight |
| Nov 11, 24 | Piper Sandler | MAINTAINED | Overweight | Overweight |
| Aug 13, 24 | Piper Sandler | MAINTAINED | Overweight | Overweight |
| May 13, 24 | Piper Sandler | MAINTAINED | Overweight | Overweight |
| Mar 6, 24 | Piper Sandler | MAINTAINED | Overweight | Overweight |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-29
Corporate Changes & Voting Matters
8-K · 2026-08-24
Periodic Financial Reports
10-Q · 2026-08-05
Corporate Changes & Voting Matters
8-K · 2026-07-15
Corporate Changes & Voting Matters
8-K · 2026-06-25
Corporate Changes & Voting Matters
8-K · 2026-06-16
Corporate Changes & Voting Matters
8-K · 2026-06-02
Specialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)
SD · 2026-06-01
Headlines
Fund Divests Cytek Biosciences (CTKB) Following Revenue Slowdown and Declining Profitability
Insider Monkey · 8d ago
Cytek® Biosciences Extends Capabilities Within Cytek Cloud Digital Ecosystem with New Cloud Analysis Tool
GlobeNewswire · 13d ago
Is the Options Market Predicting a Spike in Cytek Biosciences Bank Stock?
Zacks · 20d ago
Cytek Biosciences, Sysmex Europe Collaborate to Deliver Clinical Flow Cytometry Workflows
MT Newswires · 28d ago
Sysmex Europe and Cytek® Biosciences Collaborate to Expand Access to Advanced Clinical Flow Cytometry
GlobeNewswire · 28d ago
Cytek’s (CTKB) Instruments Keep Selling While Losses Keep Growing
Insider Monkey · 28d ago
Cytek® Biosciences Highlights the Expanding Role of Spectral Flow Cytometry in Clinical Research at ESCCA and ICCS
GlobeNewswire · 33d ago
Cytek Biosciences to Participate in Upcoming Investor Conferences
GlobeNewswire · 35d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.